Treatment

PACLITAXEL ALBUMIN-BOUND clinical trials

5 indexed studies · 0 currently recruiting

AuthorisedTherapeutic confirmatory (Phase III)
AN INTERVENTIONAL PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS PEMBROLIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER
This study looks at a new drug, PF-08634404, combined with chemotherapy for advanced lung cancer. It compares this combination to another treatment, pembrolizumab with chemotherapy, to see which works best and is safest for adults.
For: LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER
France · Italy · Hungary
AuthorisedTherapeutic exploratory (Phase II)
TAILOR-PANC: Molecularly Tailored Therapy versus Standard Care in Advanced Pancreatic Cancer (DPCG-02)
This study is looking at different individually tailored treatments for advanced pancreatic cancer. It aims to see if these personalised approaches can stop the cancer from growing for longer compared to standard care, and if they improve quality of life.
For: Advanced pancreatic cancer
Denmark
AuthorisedPhase I and Phase II (Integrated)- Other
A 2-part phase 1/2 open-label trial evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of ODM-212 in combination with anti-cancer therapy in participants with advanced solid tumours
This study is testing a new medicine called ODM-212 alongside existing cancer treatments for people with advanced solid tumours. It aims to check if the treatment is safe, how the body handles it, and if it helps shrink tumours or slow their growth.
For: Neoplasms benign malignant and unspecified (incl. cysts and polyps)
Finland · Denmark · Spain
Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3 Study of Pembrolizumab in Combination with Carboplatin/Taxane (Paclitaxel or Nab-paclitaxel) Followed by Pembrolizumab with or without Maintenance Olaparib in the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
For: Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Germany · Austria · Spain
Ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
First-In-Human, Open-Label, Dose Escalation Trial with Expansion Cohorts to Evaluate the Safety and Preliminary Efficacy of GEN1055 as Monotherapy and as Combination Therapy in Subjects with Malignant Solid Tumors.
For: Malignant Solid Tumors
Spain

AN INTERVENTIONAL PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS PEMBROLIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER

TAILOR-PANC: Molecularly Tailored Therapy versus Standard Care in Advanced Pancreatic Cancer (DPCG-02)

A 2-part phase 1/2 open-label trial evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of ODM-212 in combination with anti-cancer therapy in participants with advanced solid tumours

A Phase 3 Study of Pembrolizumab in Combination with Carboplatin/Taxane (Paclitaxel or Nab-paclitaxel) Followed by Pembrolizumab with or without Maintenance Olaparib in the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

First-In-Human, Open-Label, Dose Escalation Trial with Expansion Cohorts to Evaluate the Safety and Preliminary Efficacy of GEN1055 as Monotherapy and as Combination Therapy in Subjects with Malignant Solid Tumors.